30 April 2019
Advanced Medical Solutions Group plc
(“AMS”, the “Company” or the “Group”)
Annual Report and Accounts for the year ended
31 December 2018 and Notice of AGM
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, is pleased to announce that in accordance with AIM Rules 20 and 26, the Annual Report and Financial Statements for the year ended 31 December 2018 were posted to shareholders today and are available on the Investor Relations section of the Company’s website https://admedsol.com/Investor-Relations.
The notice of meeting convening the Annual General Meeting of the Company, which will be held on 5 June 2019 at 11 a.m. at the Guildhall Room, 85 Gresham Street, London, EC2V 7NQ, was also posted to shareholders today and is available on the Company’s website.
– Ends –
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc |
Tel: 44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer |
|
|
|
|
|
Consilium Strategic Communications |
Tel: 44 (0) 20 3709 5700 |
|
Mary-Jane Elliott / Matthew Neal / Nicholas Brown / Olivia Manser |
AMS@consilium-comms.com |
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: 44 (0) 20 7597 5970 |
|
Daniel Adams / Patrick Robb / Gary Clarence |
|
About Advanced Medical Solutions Group plc – see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and wound care markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include tissue adhesives, sutures, biosurgical devices, internal sealants, silver alginates, alginates and foams, which it markets under its brands; LiquiBand®, LiquiBand® Fix 8™, RESORBA® and ActivHeal® as well as supplying under white label.
AMS‘s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 630 employees. For more information, please see www.admedsol.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NOAIMMPTMBJJMRL